Top 5 Defensive Stocks To Watch For 2014

5 Rocket Stocks Worth Buying in September

BALTIMORE (Stockpickr) -- The first full trading week of September put an end to the five-week winning streak in the S&P 500, shoving the big index 1.1% lower between last Monday's open and Friday's close. Consider that drop a warning shot; stocks are starting to look top-heavy in September.

Read More: 5 Breakout Stocks Under $10 Set to Soar

The S&P 500 has only seen four deeper one-week declines so far in 2014, and each of those brought on a more meaningful correction this year. In other words, it makes sense to think defensively this week. To do that, we're turning to a new set of "Rocket Stock" names.

For the uninitiated, "Rocket Stocks" are our list of companies with short-term gain catalysts and longer-term growth potential. To find them, I run a weekly quantitative screen that seeks out stocks with a combination of analyst upgrades and positive earnings surprises to identify rising analyst expectations, a bullish signal for stocks in any market. After all, where analysts' expectations are increasing, institutional cash often follows. In the last 265 weeks, our weekly list of five plays has outperformed the S&P 500's record run by 81.1%.

Best Internet Stocks For 2015: ABS-CBN Corp (ABS)

ABS-CBN Corporation is primarily involved in television and radio broadcasting, as well as in the production of television and radio programming for domestic and international audiences and other related businesses. The Company operates through three business segments. Broadcasting segment is principally involved in the television and radio broadcasting activities, which generates revenue from sale of national and regional advertising time. Cable and satellite business primarily develops and produces programs for cable television, including delivery of television programming outside the Philippines through its direct-to-home (DTH) satellite service, cable television channels and blocked time on television stations. Other businesses include movie production, consumer products and services. The Company�� subsidiaries include ABS-CBN Publishing, Inc., Star Recording, Inc., Roadrunner Network, Inc., Star Songs, Inc., Sarimanok News Network, Inc. and ABS-CBN Interactive, Inc. Advisors' Opinion:

• [By John Emerson]

  During the housing bubble, lending standards were becoming relaxed and the practice of bundling subprime loans into collateralized debt obligations (CDOs) became a mainstream practice. These securities were backed by highly inflated credit ratings even though the quality of the underlying assets was highly questionable. By 2007, the worldwide demand for this type of asset-backed security (ABS) was beginning to wane and the mortgages which provided the collateral for the securities were starting to come into question.

Top 5 Defensive Stocks To Watch For 2014: Strategic Hotels and Resorts Inc (BEE)

Strategic Hotels & Resorts, Inc. (SHR), incorporated on January 27, 2004, operates as a self-administered and self-managed real estate investment trust (REIT). As of December 31, 2012, the Company�� portfolio included 18 full-service hotel interests located in urban and resort markets in the United States; Punta Mita, Nayarit, Mexico; Hamburg, Germany, and London, England. SHR conducts its operations through its direct and indirect subsidiaries, including its operating partnership, Strategic Hotel Funding, L.L.C. (SH Funding), which holds all of the Company�� assets. SHR is the sole managing member of SH Funding and held approximately 99% of its membership units as of February 27, 2013. SHR manages all business aspects of SH Funding, including the sale and purchase of hotels, the investment in these hotels and the financing of SH Funding and its assets. In September 2012, it acquired the JW Marriott Essex House Hotel in New York City. In October 2013, the Company announced that it has sold the Lakeshore Athletic Club property adjacent to the Fairmont Chicago hotel.

As of December 31, 2012, SH Funding owned interests in or leased 18 hotels, which included Fairmont Chicago, Fairmont Scottsdale Princess, Four Seasons Jackson Hole, Four Seasons Punta Mita Resort, Four Seasons Silicon Valley, Four Seasons Washington, D.C., Hotel del Coronado, Hyatt Regency La Jolla, InterContinental Chicago, InterContinental Miami, JW Marriott Essex House Hotel, Loews Santa Monica Beach Hotel, Marriott Hamburg, Marriott Lincolnshire Resort, Marriott London Grosvenor Square, Ritz-Carlton Half Moon Bay, Ritz-Carlton Laguna Niguel and Westin St. Francis.

The Hotel del Coronado is operated by a specialty management company, KSL Resorts. As of February 27, 2013, the Company wholly owned or leased 14 hotels, had a 53.5% and 51.0% interest in an affiliate that owned a hotel where it asset managed such hotel, and had 50.0% and 36.4% interests in, and acted as asset manager for, two affiliates that eac! h owned one hotel, and owned land held for development, including 20.5 acres of oceanfront land adjacent to its Four Seasons Punta Mita Resort, Nayarit, Mexico and 60 acres of oceanfront land near the Four Seasons Punta Mita Resort; a 20,000 square-foot parcel of land on the ocean in Santa Monica, California adjacent to its Loews Santa Monica Beach Hotel entitled for development and residential units; a 50% interest in an affiliate that owned 10 acres of land adjacent to the Fairmont Scottsdale Princess hotel, and a 31% interest in an affiliate with two parties that was developing the fractional ownership program known as the Four Seasons Residence Club Punta Mita.

Advisors' Opinion:

• [By Anders Bylund]

  Strategic Hotels & Resorts (NYSE: BEE  ) raised its takeover defenses in 2008 in order to ward off opportunistic raiders amid general market turmoil. The REIT, which specializes in high-end hotels, extended its poison pill last year as the "lingering economic uncertainty" never went away. Six months later, in May 2013, the extension was cut short. No real explanation, but you could take this action as a vote of confidence in an improving economy. The stock has gained 14% in the seven months since, just ahead of the S&P's 11% improvement. No takeover bids here.

• [By Rich Duprey]

  Luxury hotel and resort operator�Strategic Hotels & Resorts� (NYSE: BEE  ) �announced yesterday�its second-quarter dividend on three series of cumulative redeemable preferred stock.

• [By Marshall Hargrave]

  Well, that's exactly the case with Strategic Hotels & Resorts (NYSE: BEE), the only publicly traded real estate investment trust (REIT) that focuses exclusively on the luxury hotel and resort markets.

• [By James E. Brumley]

  In a perfect world, an investor could simply look at a company's history and its plausible earnings forecasts, and jump in (or out) knowing the stock's current price basically made sense with respect to past and future performance. We don't live or trade in a perfect world though. In the world we're actually in right now, most stocks, sectors, and industries have run up far beyond a justifiable value... perhaps except for hotel and lodging REIT stocks Host Hotels and Resorts Inc. (NYSE:HST), Strategic Hotels and Resorts Inc. (NYSE:BEE), and Pebblebrook Hotel Trust (NYSE:PEB).

Top 5 Defensive Stocks To Watch For 2014: Conatus Pharmaceuticals Inc (CNAT)

Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company�� initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).

The Company has completed two placebo-controlled Phase II trials in patients with liver disease showing reductions in ALT levels that occur rapidly, within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In the Company�� 204-patient Phase 2b trial, it also measured cCK18, an important biomarker of apoptosis and disease severity. Emricasan has been generally well-tolerated in all of the clinical studies. As of July 23, 2013, the Company had not generated any revenue.

Advisors' Opinion:

• [By John Udovich]

  While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?

• [By Lauren Pollock]

  Conatus Pharmaceuticals Inc.'s(CNAT) shares jumped 26% to $7.75 premarket after the biotechnology firm said its treatment for chronic liver disease has been granted a status that could mean quicker approval.

Top 5 Defensive Stocks To Watch For 2014: Fluidigm Corporation(FLDM)

Fluidigm Corporation engages in the development, manufacture, and marketing of microfluidic systems for growth markets in the life science and agricultural biotechnology (Ag-Bio) industries. The company?s proprietary microfluidic systems consist of instruments and consumables, including chips (integrated fluidic circuits) and reagents. Its technology enables customers to perform and measure various biochemical reactions on samples smaller than the content of a single cell by utilizing minute volumes of reagents and samples; and rapid preparation of multiple samples in parallel for next generation DNA sequencing. The company?s products include the BioMark HD system, which performs high-throughput gene expression analysis using real-time and end point PCR, SNP genotyping, single-cell analysis, and digital PCR using TaqMan, EvaGreen dye, and other chemistries; The EP1 System that performs end point PCR and is commonly used in production settings for Ag-Bio, digital PCR, and copy number variation experiments using TaqMan, EvaGreen dye, and other chemistries; and the Access Array system that enables automated sample preparation and tagging for next generation DNA sequencers. The company serves pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories, and Ag-Bio companies. Fluidigm Corporation distributes its instruments and supplies through direct field sales and support organizations in North America, Europe, and Japan; and through distributors or sales agents in parts of Europe, Latin America, the Middle East, and the Asia-Pacific region. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Advisors' Opinion:

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Fluidigm (Nasdaq: FLDM  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Fluidigm doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 24.0%, and inventory increased 14.4%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue expanded 32.8%, and inventory increased 14.4%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 7.2%, and inventory grew 2.8%.

• [By Sean Williams]

  What: Shares of Fluidigm (NASDAQ: FLDM  ) , a manufacturer of microfluidic systems for the biotech, pharmaceutical, and academic research sectors, shot higher by as much as 14% after reporting its first-quarter-earnings results.

• [By Seth Jayson]

  Fluidigm (Nasdaq: FLDM  ) reported earnings on May 1. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Fluidigm beat slightly on revenues and exceeded expectations on earnings per share.

• [By John Kell]

  Bio-technology company Fluidigm Corp.(FLDM) agreed to acquire DVS Sciences Inc. for about $208 million to expand its portfolio of single-cell technology products. DVS manufactures and distributes bioanalytical products for biological research and future clinical applications. Shares dropped 2.3% to $40.02 premarket.